Comparative pharmacokinetics of two extended half-life FVIII concentrates (Eloctate and Adynovate) in adolescents with hemophilia A: Is there a difference?
- 30 June 2019
- journal article
- research article
- Published by Elsevier BV in Journal of Thrombosis and Haemostasis
- Vol. 17 (7), 1085-1096
- https://doi.org/10.1111/jth.14469
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Defining extended half-life rFVIIIA critical review of the evidenceHaemophilia, 2018
- Cross-evaluation of Pharmacokinetic-Guided Dosing Tools for Factor VIIIThrombosis and Haemostasis, 2018
- Development of a Web-Accessible Population Pharmacokinetic Service—Hemophilia (WAPPS-Hemo): Study ProtocolJMIR Research Protocols, 2016
- Data Analysis Protocol for the Development and Evaluation of Population Pharmacokinetic Models for Incorporation Into the Web-Accessible Population Pharmacokinetic Service - Hemophilia (WAPPS-Hemo)JMIR Research Protocols, 2016
- When and how to start prophylaxis in boys with severe hemophilia without inhibitors: communication from the SSC of the ISTHJournal of Thrombosis and Haemostasis, 2016
- Pegylated, full-length, recombinant factor VIII for prophylactic and on-demand treatment of severe hemophilia ABlood, 2015
- Changing paradigm of prophylaxis with longer acting factor concentratesHaemophilia, 2014
- Phase I study of BAY 94‐9027, a PEGylated B‐domain‐deleted recombinant factor VIII with an extended half‐life, in subjects with hemophilia AJournal of Thrombosis and Haemostasis, 2014
- Phase 3 Study of Recombinant Factor IX Fc Fusion Protein in Hemophilia BNew England Journal of Medicine, 2013
- Population pharmacokinetic modeling for dose setting of nonacog beta pegol (N9‐GP), a glycoPEGylated recombinant factor IXJournal of Thrombosis and Haemostasis, 2012